# Phase 1 Carcinoma, Renal Cell trials recruiting: 49 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials in phase 1 for Carcinoma, Renal Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Carcinoma, Renal Cell trials: 49 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/carcinoma-renal-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 49
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 30, 2026 | NCT07848295 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma (ccRCC) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848295) |
| August 18, 2026 | NCT07770802 | Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01) | Hangzhou Huasai Biomedicine Co., Ltd. | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770802) |
| August 17, 2026 | NCT07768306 | Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in... | Norroy Bioscience Co., LTD | Phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma (ccRCC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768306) |
| August 6, 2026 | NCT07748988 | Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma | Vanderbilt-Ingram Cancer Center | Phase 1 | Recruiting | Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748988) |
| July 21, 2026 | NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney... | Jonsson Comprehensive Cancer Center | Phase 1 | Not yet recruiting | Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716735) |
| July 7, 2026 | NCT07688187 | A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma | PeptiDream Inc. | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688187) |
| July 7, 2026 | NCT07686744 | Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Renal Cell Carcinoma, Advanced, Recurrent, Refractory | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686744) |
| June 15, 2026 | NCT07647744 | To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer | Hrain Biotechnology Co., Ltd. | Phase 1 | Recruiting | Renal Cell Carcinoma (RCC) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647744) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| May 4, 2026 | NCT07564232 | Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564232) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| March 30, 2026 | NCT07500805 | UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma | UTC Therapeutics Inc. | Phase 1 | Not yet recruiting | CD70-positive Advanced Renal Clear Cell Carcinoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07500805) |
| February 19, 2026 | NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Compass Therapeutics | Phase 1 | Recruiting | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419841) |
| January 27, 2026 | NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | SAPU NANO (US) LLC | Phase 1 | Recruiting | Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369505) |
| December 23, 2025 | NCT07300241 | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | Neomorph, Inc | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300241) |
| December 22, 2025 | NCT07297667 | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | Canadian Cancer Trials Group | Phase 1 | Recruiting | Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297667) |
| November 28, 2025 | NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | AccSalus Biosciences, Inc. | Phase 1 | Not yet recruiting | Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252661) |
| September 29, 2025 | NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Incyte Corporation | Phase 1 | Recruiting | Solid Tumors, Hematologic Malignancies | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195916) |
| September 29, 2025 | NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Bristol-Myers Squibb | Phase 1 | Recruiting | Renal Cell Carcinoma | 281 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195682) |
| September 23, 2025 | NCT07187869 | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof... | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187869) |
| August 19, 2025 | NCT07128680 | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell... | City of Hope Medical Center | Phase 1 | Recruiting | Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell... | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128680) |
| July 14, 2025 | NCT07062549 | Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | Recruiting | Renal Cell Carcinoma (Kidney Cancer) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07062549) |
| May 11, 2025 | NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | Deciphera Pharmaceuticals, LLC | Phase 1 | Recruiting | Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966024) |
| April 24, 2025 | NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | Sponsor not shown (see the record) | Phase 1 | Recruiting | Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell... | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06942104) |
| April 4, 2025 | NCT06910657 | IDOV-Immune for Advanced Solid Tumors | ViroMissile, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06910657) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 3 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| [Arcus Biosciences, Inc.](https://specstream.ai/data/clinical-trials/company/arcus-biosciences-inc) | 1 |
| Novelty Nobility, Inc. | 1 |
| Nammi Therapeutics Inc | 1 |
| Hangzhou Huasai Biomedicine Co., Ltd. | 1 |
| ViroMissile, Inc. | 1 |
| HiberCell, Inc. | 1 |
| Calico Life Sciences LLC | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |
| AccSalus Biosciences, Inc. | 1 |
| LaunXP Biomedical Co., Ltd. | 1 |
| Sairopa B.V. | 1 |
| Zhejiang University | 1 |
| City of Hope Medical Center | 1 |
| [Xencor, Inc.](https://specstream.ai/data/clinical-trials/company/xencor-inc) | 1 |
| Kura Oncology, Inc. | 1 |
| SAPU NANO (US) LLC | 1 |
| [LG Chem](https://specstream.ai/data/clinical-trials/company/lg-chem) | 1 |
| Shanghai Junshi Bioscience Co., Ltd. | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 34 |
| Spain | 9 |
| Australia | 8 |
| China | 8 |
| France | 6 |
| Belgium | 5 |
| Italy | 5 |
| Germany | 3 |
| United Kingdom | 3 |
| Canada | 3 |
| Israel | 2 |
| Poland | 2 |
| South Korea | 2 |
| Denmark | 1 |
| Austria | 1 |
| New Zealand | 1 |
| Switzerland | 1 |
| Netherlands | 1 |
| Japan | 1 |
| Taiwan | 1 |
| Croatia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pakistani restaurants in the United States](https://specstream.ai/data/businesses/pakistani-restaurants/united-states)
- [Research institutes in the United States](https://specstream.ai/data/businesses/research-institutes/united-states)
- [Textile mills in the United States](https://specstream.ai/data/businesses/textile-mills/united-states)
- [Agricultural cooperatives in the United States](https://specstream.ai/data/businesses/agricultural-cooperatives/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
- [Construction management firms in the United States](https://specstream.ai/data/businesses/construction-management-firms/united-states)
